Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

NCT06827236 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06827236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06827236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 23, 2025
Completion date
August 31, 2029
Enrollment
380 (estimated)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced breast cancer, metastatic breast cancer, unresectable breast carcinoma